Evidence map›Paper›PMID 42591477›Full record

ArticleTranslational cancer research2026

Xuefei Wu, Fei Ding, Weijie Wu, Honghua Dong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xuefei Wu *Department of Orthopaedics, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng, China.
Fei Ding *Department of Orthopaedics, Affiliated Nantong Hospital of Shanghai University, The Sixth People's Hospital of Nantong, Nantong, China.
Weijie WuDepartment of Orthopaedics, Affiliated Nantong Hospital of Shanghai University, The Sixth People's Hospital of Nantong, Nantong, China.
Honghua DongDepartment of Orthopaedics, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Osteosarcoma (OS) is the most common primary bone malignancy in adolescents, but its pathogenesis remains poorly understood. Creatine kinase mitochondrial 2 ( Methods: Bioinformatics analyses were conducted using Gene Expression Omnibus (GEO) and Therapeutically Applicable Research to Generate Effective Treatments (TARGET) databases. Western blotting evaluated Results: Conclusions:

Indexed as

bioinformaticscell proliferationCreatine kinase mitochondrial 2 (CKMT2)osteosarcoma (OS)prognostic biomarker

Identifiers

PMID42591477
PMCPMC13462118

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.